These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
288 related items for PubMed ID: 26346366
1. 2D and 3D QSAR models for identifying diphenylpyridylethanamine based inhibitors against cholesteryl ester transfer protein. Chen M, Yang X, Lai X, Gao Y. Bioorg Med Chem Lett; 2015 Oct 15; 25(20):4487-95. PubMed ID: 26346366 [Abstract] [Full Text] [Related]
2. Cholesteryl ester transfer protein inhibitors in coronary heart disease: Validated comparative QSAR modeling of N, N-disubstituted trifluoro-3-amino-2-propanols. Mondal C, Halder AK, Adhikari N, Jha T. Comput Biol Med; 2013 Oct 15; 43(10):1545-55. PubMed ID: 24034746 [Abstract] [Full Text] [Related]
3. 2D Quantitative structure-activity relationship studies on a series of cholesteryl ester transfer protein inhibitors. Castilho MS, Guido RV, Andricopulo AD. Bioorg Med Chem; 2007 Sep 15; 15(18):6242-52. PubMed ID: 17604633 [Abstract] [Full Text] [Related]
4. Reliable structural information for rational design of benzoxazole type potential cholesteryl ester transfer protein (CETP) inhibitors through multiple validated modeling techniques. Amin SA, Adhikari N, Gayen S, Jha T. J Biomol Struct Dyn; 2019 Oct 15; 37(17):4528-4541. PubMed ID: 30488780 [Abstract] [Full Text] [Related]
5. Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors. Wang Y, Yang W, Finlay HJ, Harikrishnan LS, Jiang J, Kamau MG, Van Kirk K, Nirschl DS, Taylor DS, Chen AY, Yin X, Sleph PG, Yang RZ, Huang CS, Adam LP, Lawrence RM, Wexler RR, Salvati ME. Bioorg Med Chem Lett; 2014 Feb 01; 24(3):860-4. PubMed ID: 24424134 [Abstract] [Full Text] [Related]
8. New Research for Quinazoline-2,4-diones as HPPD Inhibitors Based on 2D-MLR and 3D-QSAR Models. Fu Y, Sun YN, Cao HF, Yi KH, Zhao LX, Li JZ, Ye F. Comb Chem High Throughput Screen; 2017 Feb 01; 20(9):748-759. PubMed ID: 28637410 [Abstract] [Full Text] [Related]
9. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models. Bhongade BA, Gadad AK. J Med Chem; 2006 Jan 26; 49(2):475-89. PubMed ID: 16420035 [Abstract] [Full Text] [Related]
11. 2D QSAR studies on a series of (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-1,3-oxazolidin-2-one as CETP inhibitors. Bitam S, Hamadache M, Salah H. SAR QSAR Environ Res; 2020 Jun 26; 31(6):423-438. PubMed ID: 32476475 [Abstract] [Full Text] [Related]
14. Quantitative structure-activity relationship study on BTK inhibitors by modified multivariate adaptive regression spline and CoMSIA methods. Xu A, Zhang Y, Ran T, Liu H, Lu S, Xu J, Xiong X, Jiang Y, Lu T, Chen Y. SAR QSAR Environ Res; 2015 Jun 26; 26(4):279-300. PubMed ID: 25906044 [Abstract] [Full Text] [Related]
15. P56(lck) kinase inhibitor studies: a 3D QSAR approach towards designing new drugs from flavonoid derivatives. Gunda SK, Narasimha SK, Shaik M. Int J Comput Biol Drug Des; 2014 Jun 26; 7(2-3):278-94. PubMed ID: 24878734 [Abstract] [Full Text] [Related]
20. New p-methylsulfonamido phenylethylamine analogues as class III antiarrhythmic agents: design, synthesis, biological assay, and 3D-QSAR analysis. Liu H, Ji M, Luo X, Shen J, Huang X, Hua W, Jiang H, Chen K. J Med Chem; 2002 Jul 04; 45(14):2953-69. PubMed ID: 12086482 [Abstract] [Full Text] [Related] Page: [Next] [New Search]